摘要
目的探讨重组人脑利钠肽联合左西孟旦治疗难治性心力衰竭的疗效及安全性。方法收集2017年4月—2019年3月期间在本院住院治疗的难治性心衰患者106例。根据随机数字表法将患者分为联合组和对照组,每组53例。对照组在常规治疗基础上给予重组人脑利钠肽治疗。联合组在对照组基础上加左西孟旦注射液治疗。比较两组治疗前后左室射血分数(left ventricular ejection fraction,LVEF)、每搏输出量(stroke volume,SV)和呼吸困难程度变化及治疗期间不良反应发生情况,并对比两组的临床疗效。结果治疗后,联合组LVEF、SV明显高于对照组,差异有统计学意义(P<0.05),呼吸困难评分明显低于对照组,差异有统计学意义(P<0.05)。联合组总有效率明显高于对照组,差异有统计学意义(P<0.05),两组不良反应发生率比较差异无统计学意义(P>0.05)。结论重组脑利钠肽联合左西孟旦治疗难治性心力衰竭可有效提高患者的LVEF和SV,改善呼吸困难症状,提高整体疗效。
Objective To investigate the efficacy and safety of recombinant human brain natriuretic peptide(rhBNP)combined with levosimendan in the treatment of refractory heart failure.Methods 106 patients with refractory heart failure from April 2017 to March 2019 were collected.According to the random number table method,the patients were divided into the combined group and the control group,with 53 cases in each group.The control group was treated with recombinant human brain natriuretic peptide on the basis of routine treatment.The combination group was treated with levosimendan injection on the basis of the control group.The left ventricular ejection fraction(LVEF),stroke volume(SV),the degree of dyspnea and the occurrence of adverse reactions during treatment were compared between the two groups before and after treatment.And compare the clinical efficacy of the two groups.Results After treatment,the LVEF and SV of the combined group were significantly higher than those of the control group,the difference was statistically significant(P<0.05),and the dyspnea score was significantly lower than that of the control group,the difference was statistically significant(P<0.05).The total effective rate of the combined group was significantly higher than that of the control group,the difference was statistically significant(P<0.05),and there was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Recombinant brain natriuretic peptide combined with levosimendan in the treatment of refractory heart failure can effectively improve the LVEF and SV of patients,improve the symptoms of dyspnea and improve the overall efficacy.
作者
宋宁
SONG Ning(Department of Cardiology,Jining First People's Hospital,Jining Shandong 272000,China)
出处
《中国卫生标准管理》
2020年第1期67-69,共3页
China Health Standard Management
关键词
重组人脑利钠肽
左西孟旦
难治性心力衰竭
心功能
左室射血分数
呼吸困难
recombinant human brain natriuretic peptide
levosimendan
refractory heart failure
cardiac function
left ventricular ejection fraction
dyspnea
